Valuation: Alkermes plc

Market Cap 832.27Cr 720.83Cr 671.94Cr 618.01Cr 1.17TCr 79TCr 1.18TCr 7.9TCr 3.1TCr 40TCr 3.13TCr 3.06TCr 1,31100Cr P/E 2026 *
-97.4x
P/E 2027 * 68.2x
Enterprise Value 906.67Cr 785.26Cr 732.01Cr 673.25Cr 1.27TCr 86TCr 1.29TCr 8.6TCr 3.38TCr 43TCr 3.41TCr 3.33TCr 1,42900Cr EV / Sales 2026 *
4.97x
EV / Sales 2027 * 4.62x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day-0.12%
1 week+2.63%
Current month+1.27%
1 month-9.11%
3 months+36.86%
6 months+47.87%
Current year+77.31%
1 week 48.19
Extreme 48.19
50.85
1 month 47.66
Extreme 47.66
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Sell

Compliance Officer

-2,034 0.0012%
03/08/26 Fiscal year

Chief Technology Officer

19,000 0.0114%
03/08/26 Fiscal year

Director

1,33,416 0.0800%
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%+2.63%+86.50%+79.75% 833.28Cr
+0.90%-2.33%+0.68%+13.87% 4.8TCr
+1.98%+9.05%+413.94%+532.17% 4.11TCr
+3.44%-4.65%+28.34%+8.81% 3.76TCr
+1.40%+0.10%+6.61%+61.93% 3.59TCr
+2.42%+5.72%+12.38%+44.79% 2.99TCr
-0.16%-3.11% - - 1.61TCr
+2.20%+0.48%+34.71%+127.15% 1.61TCr
+1.25%+1.52%+4.62%+18.26% 1.38TCr
+4.25%-8.23%-1.49%-35.46% 1.21TCr
Average +1.76%-0.42%+65.14%+94.59% 2.59TCr
Weighted average by Cap. +1.84%+0.08%+82.62%+119.38%

Financials

2026 *2027 *
Net sales 182.49Cr 158.05Cr 147.33Cr 135.51Cr 255.82Cr 17TCr 258.68Cr 1.73TCr 679.54Cr 8.68TCr 685.39Cr 670.28Cr 29TCr 194.46Cr 168.42Cr 157Cr 144.4Cr 272.6Cr 18TCr 275.64Cr 1.84TCr 724.1Cr 9.25TCr 730.35Cr 714.25Cr 31TCr
Net income -8.99Cr -7.79Cr -7.26Cr -6.68Cr -13Cr -855.01Cr -13Cr -85Cr -33Cr -427.81Cr -34Cr -33Cr -1.42TCr 12Cr 10Cr 9.71Cr 8.93Cr 17Cr 1.14TCr 17Cr 114.12Cr 45Cr 572.29Cr 45Cr 44Cr 1.9TCr
Net Debt 74Cr 64Cr 60Cr 55Cr 104.29Cr 7.07TCr 105.45Cr 705.79Cr 277.01Cr 3.54TCr 279.4Cr 273.24Cr 12TCr 67Cr 58Cr 54Cr 50Cr 94Cr 6.37TCr 95Cr 635.59Cr 249.46Cr 3.19TCr 251.61Cr 246.06Cr 11TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
05/26/05 $49.61 -0.12% 17,06,768
04/26/04 $49.67 +0.28% 14,30,842
03/26/03 $49.53 +1.10% 18,35,762
31/26/31 $48.99 -2.08% 16,24,487
30/26/30 $50.03 +3.50% 23,03,338
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.61USD
Average target price
56.00USD
Spread / Average Target
+12.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock